drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy (CAR T)
drug_description
Autologous BCMA-directed CAR T-cell therapy in which a patient’s T cells are engineered to express an anti-BCMA CAR to recognize and kill myeloma plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Idecabtagene Vicleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express an anti-BCMA chimeric antigen receptor (with costimulatory and CD3ζ signaling domains). Upon binding BCMA on myeloma plasma cells, the CAR T cells activate, proliferate, release cytotoxic granules and cytokines, and lyse BCMA-expressing tumor cells.
drug_name
Idecabtagene vicleucel (ide-cel)
nct_id_drug_ref
NCT06179888